Skip to main content

An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and / or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread

Trial Status: Active

The purpose of the study is to determine the safety and tumor-shrinking ability of experimental medication BMS-986178, when given by itself or in combination with Nivolumab and / or Ipilimumab, in patients with solid cancers that are advanced or have spread.

Inclusion Criteria

  • Patients must have at least 1 standard treatment regimen in the advanced, recurrent or metastatic setting
  • ECOG (Eastern Cooperative Oncology Group) 0-1
  • Men and women 18 years old or older
  • At least one measurable lesion at baseline by CT (computed tomography) or MRI (magnetic resonance imaging) as per RECIST (Response Evaluation Criteria In Solid Tumors) v1.1
  • All subjects must have a fresh tumor biopsy

Exclusion Criteria

  • Known central nervous system metastases or central nervous system as the only source of disease
  • Concomitant malignancies
  • Active known or suspected autoimmune disease
  • Uncontrolled or significant cardiovascular disease
  • Major surgery less than 4 weeks before the start of the study
  • Patients with known allergies to egg products, neomycin, or tetanus toxoid
  • Prior adverse reaction to tetanus toxoid-containing vaccines

Colorado

Aurora
University of Colorado Hospital
Status: CLOSED_TO_ACCRUAL

Maryland

Baltimore
Johns Hopkins University / Sidney Kimmel Cancer Center
Status: ACTIVE

New York

Buffalo
Roswell Park Cancer Institute
Status: ACTIVE
New York
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: ACTIVE
Contact: Richard D. Carvajal
Phone: 646-317-3141

Oregon

Portland
OHSU Knight Cancer Institute
Status: ACTIVE

Pennsylvania

Philadelphia
Fox Chase Cancer Center
Status: CLOSED_TO_ACCRUAL
Contact: Anthony J. Olszanski
Phone: 215-214-1676

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
Bristol-Myers Squibb

  • Primary ID CA012-004
  • Secondary IDs NCI-2016-01179, 2015-004816-39
  • Clinicaltrials.gov ID NCT02737475